Catalys Pacific is a venture capital firm specializing in early-stage investments within the healthcare, pharmaceuticals, biotechnology, and life sciences sectors in the United States and Japan. Their strategy involves a "venture creation" model, establishing and funding asset-centric biotech companies to drive innovation and provide solutions for unmet medical needs globally, leveraging transpacific partnerships.
100% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-a (60% of deals). Average disclosed round size is $103.0M (across 5 rounds with reported amounts).
Portfolio
5
Fund Size
—
Top Stage
Series A
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
5 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Crystalys Therapeutics Inc. | Series A | $205M | Sep 2025 |
 Pathalys Pharma, Inc. | Series B | $105M | Aug 2024 |
| Pathalys Pharma, Inc. | Growth | $150M | Jan 2023 |
 Mineralys Therapeutics, Inc. | Series A | $40M | Apr 2021 |
 Exalys Therapeutics Inc. | Series A | $15M | Jul 2020 |
Top Co-Investors
Samsara BioCapital2 shared
KB Partners2 shared
Adams Street1 shared
J.P. Morgan Life Sciences Private Capital1 shared
Marshall Wace1 shared
Domain Associates1 shared
Abingworth1 shared
The Carlyle Group1 shared
OrbiMed1 shared
DaVita Venture Group1 shared
Novo Holdings1 shared
Pontifax1 shared
Alexandria Venture Investments1 shared
Wedbush Healthcare Partners1 shared
Last updated: 8 March 2026